Eberhard-Karls-Universität Tübingen, Interfakultäres Institut für Mikrobiologie und Infektionsmedizin (IMIT), Mikrobiologie/Biotechnologie, Auf der Morgenstelle 28, 72076 Tübingen, Germany.
Antimicrob Agents Chemother. 2011 Sep;55(9):4283-9. doi: 10.1128/AAC.01372-10. Epub 2011 Jun 20.
The prevailing resistance mechanism against glycopeptides in Gram-positive pathogens involves reprogramming the biosynthesis of peptidoglycan precursors, resulting in d-alanyl-d-lactate depsipeptide termini. Amycolatopsis balhimycina produces the vancomycin-like glycopeptide balhimycin and therefore has to protect itself from the action of the glycopeptide. We studied the roles of the accessory resistance gene orthologs vanY(b), vnlR(b), and vnlS(b), which are part of the balhimycin biosynthetic gene cluster (represented by the subscript "b"). The VanY(b) carboxypeptidase cleaved the terminal d-Ala from peptidoglycan precursors, and its heterologous expression enhanced glycopeptide resistance in Streptomyces coelicolor. The VanRS-like two component system VnlRS(b) was not involved in glycopeptide resistance or in the expression of the vanHAX glycopeptide resistance genes. Mature A. balhimycina peptidoglycan contained mainly tri- and tetrapeptides, with only traces of the d-Ala-d-Ala-ending pentapeptides that are binding sites for the antibiotic produced. The structure of the peptidoglycan precursor is consistent with the presence of vanHAX genes, which were identified outside the balhimycin synthesis cluster. Both wild-type and non-antibiotic-producing mutant strains synthesized peptidoglycan precursors ending mainly with d-Lac, indicating constitutive synthesis of a resistant cell wall. A. balhimycina could provide a model for an ancestral glycopeptide producer with constitutively expressed resistance genes.
革兰氏阳性病原体对糖肽类药物的主要耐药机制涉及对肽聚糖前体生物合成的重新编程,导致产生 d-丙氨酰-d-乳酸去缩肽末端。Amycolatopsis balhimycina 产生类似于万古霉素的糖肽类药物 balhimycin,因此必须保护自己免受糖肽类药物的作用。我们研究了辅助耐药基因 orthologs vanY(b)、vnlR(b) 和 vnlS(b) 的作用,它们是 balhimycin 生物合成基因簇的一部分(用下标“b”表示)。VanY(b) 羧肽酶从肽聚糖前体中切割末端的 d-Ala,其异源表达增强了变铅青链霉菌中的糖肽类药物耐药性。VanRS 样双组分系统 VnlRS(b) 不参与糖肽类药物耐药性或 vanHAX 糖肽类药物耐药基因的表达。成熟的 A. balhimycina 肽聚糖主要含有三肽和四肽,只有痕量的 d-Ala-d-Ala 结尾的五肽,五肽是产生抗生素的结合位点。肽聚糖前体的结构与 vanHAX 基因的存在一致,vanHAX 基因被鉴定为在 balhimycin 合成簇之外。野生型和非抗生素产生突变株均合成主要以 d-Lac 结尾的肽聚糖前体,表明其细胞壁具有组成型耐药性。A. balhimycina 可以为具有组成型表达耐药基因的原始糖肽类药物产生菌提供模型。